Clinical Conductor Adds CTMS Features to Facilitate Dynamic Research
The team behind Clinical Conductor CTMS recently debuted new functionality that allows healthcare organizations to better manage adaptive and dynamic clinical research that is becoming more relevant in the industry every year.
The team behind Clinical Conductor CTMS recently debuted new functionality that allows healthcare organizations to better manage adaptive and dynamic clinical research that is becoming more relevant in the industry every year.
This quarter, the development team has added unique features including:
· Budget snapshots for better financial management and negotiations with sponsors
· The ability for organizations to create multiple charge masters
· Protocol versioning – where organizations can create new versions of a protocol and more easily handle amendments that occur
All of these features help solve an existing problem in research where technology can sometimes be lacking: flexibility. Since research is continuously changing, researchers and managers need technology capable of providing the granular data they need to remain profitable and produce high quality clinical research.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
